the article talks about 20 stocks that are moving in the pre-market. This means that before the market opens, these stocks are already changing in price. The article mentions that Exicure shares are trading higher by over 49%. This means that Exicure's stock price is going up a lot in the pre-market. The article also tells us about other stocks that are gaining or losing value in the pre-market. Read from source...

-
My response:

First, let me clarify that the text provided is not a personal story, but rather a news article discussing the rise of Exicure shares and the 20 other stocks moving in the pre-market trading session.

As for the content of the article, it seems to provide a factual and concise overview of the market movement on that day. It presents the stocks that gained and lost in the pre-market trading, with specific details on the percentage increase or decrease and reasons for such movement.

Overall, the article appears to be written in a neutral and objective manner, without any evident inconsistencies, biases, irrational arguments, or emotional behavior.

If you have any specific concerns or points you would like me to address, please feel free to provide more details or clarify your questions.

The sentiment of the article titled `Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket` is bullish.

1. Exicure (XCUR) - BUY, with a target price of $3.50. Exicure shares are currently trading at $2.39, after a 49.3% jump in pre-market trading due to the company's debt-for-equity exchange agreements and regained Nasdaq compliance. Risk: Exicure's financial position and the success of its ongoing and future clinical trials.

2. NuCana (NCNA) - BUY, with a target price of $7.50. NuCana shares are currently trading at $4.94, after a 94.4% jump in pre-market trading due to the positive final data from Phase 2 Nutide:701 study for NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. Risk: NuCana's ability to generate significant revenue and achieve profitability.

3. Dermata Therapeutics (DRMA) - BUY, with a target price of $3.50. Dermata shares are currently trading at $2.74, after a 73.4% jump in pre-market trading. Risk: Dermata's limited financials and the success of its ongoing and future clinical trials.

4. Agape ATP (ATPC) - BUY, with a target price of $4.00. Agape ATP shares are currently trading at $2.68, after a 53.1% jump in pre-market trading due to the strategic collaboration with Xiamen Photons Solar Technology for developing solar photovoltaic mounting systems in ASEAN countries. Risk: Agape ATP's limited financials and the success of its ongoing and future business ventures.

5. Tenon Medical (TNON) - BUY, with a target price of $13.00. Tenon Medical shares are currently trading at $9.22, after gaining around 72% on Friday due to the pricing of a $4.5 million public offering of 1.22 million shares and warrants. Risk: Tenon Medical's limited financials and the success of its ongoing and future clinical trials and regulatory approvals.

6. iTeos Therapeutics (ITOS) - BUY, with a target price of $30.00. iTeos Therapeutics shares are currently trading at $20.05, after a 20.1% jump in pre-market trading due to the follow- up interim data from GALAXIES Lung-201 Phase 2 platform study for Belrestotug+Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD- L1 high non-small cell lung cancer. Risk: iTeos Therapeutics' ability to generate significant revenue and achieve profitability.

7. IO Biotech (IOBT) - BUY, with a target price of $1.50. IO Biotech shares